Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipid homeostasis is a fundamental physiological process that maintains a stable internal environment of various lipids, including cholesterol, triglycerides, and phospholipids, which are essential for cell membrane integrity, energy storage, and signaling [1]. This balance is achieved through a complex network of feedback mechanisms involving key regulators such as Sterol Regulatory Element-Binding Proteins (SREBPs) and Peroxisome Proliferator-Activated Receptors (PPARs), which control the expression of genes involved in lipid synthesis, uptake, and transport [2]. Dysregulation of lipid homeostasis is a central driver of several metabolic and cardiovascular diseases, most notably atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes [3]. While many therapeutic agents, such as statins and fibrates, are designed to restore lipid balance by targeting specific enzymes or receptors within this network, 'Lipid homeostasis' itself represents a broad biological state rather than a single druggable molecular entity [4]. Consequently, it is classified as a biological process and is considered an incorrect term when used to describe a specific therapeutic target in a pharmaceutical context [5]. Sources: [1] Nature Reviews Molecular Cell Biology (2020), 'Principles of lipid homeostasis'. [2] Journal of Clinical Investigation (2002), 'SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver'. [3] National Institutes of Health (NIH), 'Cholesterol and Lipid Metabolism'. [4] European Heart Journal (2020), 'ESC/EAS Guidelines for the management of dyslipidaemias'. [5] PubMed/NCBI Taxonomy and GO Term databases.
Lipid homeostasis is not a single molecular target but a physiological process; drugs modulate it by targeting specific enzymes (e.g., HMG-CoA reductase), transporters (e.g., NPC1L1), or receptors (e.g., PPAR-alpha) to alter lipid synthesis, absorption, and clearance.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipid homeostasis.